The use of Spectral Shift in identifying Microcycle® hits for challenging therapeutic targets

Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic disorder and lack of small molecule binding pockets make them intractable to small molecule approaches. One modality that has shown potential when employed against these targets is cyclic peptides.

In this talk, Dr. Gardner will explore how the Dianthus instrument with Spectral Shift technology has been integrated into Curve Therapeutics' screening cascade to validate cyclic peptide hits. He will present results with a focus on assay development, affinity screening, data processing, and a comparison of the results he obtained from the two biophysical technologies available in Dianthus.

No Previous Videos

Up next
Screening for p38 ligands: From assay optimization to lead validation in 2 days
Screening for p38 ligands: From assay optimization to lead validation in 2 days

Dianthus is a biophysical screening instrument that uses Spectral Shift technology to measure molecular int...

Ready to tackle your challenging affinity screening?

Discover tools you can use

Learn more